Peer-Reviewed Journal Details
Mandatory Fields
English, K;Ryan, JM;Tobin, L;Murphy, MJ;Barry, FP;Mahon, BP
2009
April
Clinical And Experimental Immunology
Cell contact, prostaglandin E-2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4(+)CD25(High)forkhead box P3(+) regulatory T cells
Published
WOS: 319 ()
Optional Fields
VERSUS-HOST-DISEASE THERAPY POSITION STATEMENT STROMAL CELLS DENDRITIC CELLS TGF-BETA LYMPHOCYTE-PROLIFERATION CONTROLLING AUTOIMMUNITY INTERNATIONAL-SOCIETY PERIPHERAL-BLOOD INTERFERON-GAMMA
156
149
160
Adult human mesenchymal stromal or stem cells (MSC) can differentiate into a variety of cell types and are candidate cellular therapeutics in regenerative medicine. Surprisingly, these cells also display multiple potent immunomodulatory capabilities, including allosuppression, making allogeneic cell therapy a possibility. The exact mechanisms involved in regulatory T cell induction by allogeneic human MSC was examined, using purified CD4(+) populations and well-characterized bone marrow-derived adult human MSC. Allogeneic MSC were shown to induce forkhead box P3 (FoxP3)(+) and CD25(+) mRNA and protein expression in CD4(+) T cells. This phenomenon required direct contact between MSC and purified T cells, although cell contact was not required for MSC induction of FoxP3 expression in an unseparated mononuclear cell population. In addition, through use of antagonists and neutralizing antibodies, MSC-derived prostaglandins and transforming growth factor (TGF)-beta 1 were shown to have a non-redundant role in the induction of CD4(+)CD25(+)FoxP3(+) T cells. Purified CD4(+)CD25(+) T cells induced by MSC co-culture expressed TGF-beta 1 and were able to suppress alloantigen-driven proliferative responses in mixed lymphocyte reaction. These data clarify the mechanisms of human MSC-mediated allosuppression, supporting a sequential process of regulatory T cell induction involving direct MSC contact with CD4(+) cells followed by both prostaglandin E-2 and TGF-beta 1 expression. Overall, this study provides a rational basis for ongoing clinical studies involving allogeneic MSC.
0009-9104
10.1111/j.1365-2249.2009.03874.x
Grant Details
Publication Themes